Economic Impact of Biosimilars Save

According to the Federal Trade Commission biosimilars have the potential to save the U.S. healthcare system $250 billion through 2022. Furthermore, the global biosimilars market, according to an analysis by Frost & Sullivan, “will see exponential growth” over the next decade. This growth will not just save the healthcare system money. It can also improve patient outcomes and be a significant economic driver.   In Europe, biosimilars are already seeing discounts greater than 30%.